On October 3, 2013, Spectrum Pharmaceuticals, Inc. (the "Company"), entered into an Amendment (the "Amendment") to the License and Collaboration Agreement, dated February 2, 2010, as amended, by and between the Company and Topotarget A/S, a Danish corporation ("Topotarget"). Under the Amendment, among other things, the parties agreed to restructure the agreement to provide the Company with the right and the responsibility to manufacture (either through itself or one or more contract manufacturers) clinical, commercial and named patient supplies of Belinostat world-wide for an initial period from the amendment effective date through the date that is five (5) years from the new drug application approval date and Topotarget being relieved of its existing responsibility regarding the same. Additionally, the parties agreed for Topotarget to purchase its requirements from the Company based on periodic forecasts and at cost plus percentage for such supplies. After the initial period, absent notices of termination, the supply arrangement shall continue for renewable periods.
Well, SPPI just ACQUIRED the (i) gross revenues and (ii) net margins related to the Manufacturer's component of all Belinostat Sales anywhere in the World.
Previously, SPPI only had U.S. (or perhaps North American) rights to Belinostat and just added the Manufacturing component of revenues and profits for the ROW. There are certain outs under this Amendment for the Worldwide Manufacturing Rights but it sounds like a win/win to me for SPPI.